Literature DB >> 30539797

miR-122 enhances sensitivity of hepatocellular carcinoma to oxaliplatin via inhibiting MDR1 by targeting Wnt/β-catenin pathway.

Fei Cao1, Li-Xue Yin2.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the primary causes of cancer-related death and resistance to cytotoxic chemotherapy is the major cause of mortality in HCC patients. miR-122 is a liver specific miRNA and is found to be reduced in HCC, however, the function of miR-122 in HCC chemosensitivity remains elusive.
METHODS: We used qRT-PCR to measure expressions of miR-122, β-catenin and MDR1 in four HCC cell lines. And we assessed the effects of miR-122 or β-catenin on cell viability and apoptosis upon oxaliplatin (OXA) treatment by MTT assay and flow cytometry. In addition, we validated the interactions of miR-122/β-catenin and β-catenin/MDR1 by dual luciferase reporter assay and chromatin immunoprecipitation (ChIP). Western blotting was used to determine the protein levels of β-catenin, Wnt1 and MDR1. In the end, we verified the anti-tumor effect of miR-122 in vivo by using mouse tumor xenograft model.
RESULTS: We found that miR-122 was down-regulated in HCC cells. Up-regulation of miR-122 or inhibition of Wnt/β-catenin signaling promoted HCC cells apoptosis and increased the sensitivity of HCC cells to OXA. On the molecular level, we showed that miR-122 directly targeted and suppressed Wnt/β-catenin pathway while β-catenin bound with MDR1 promoter and activated its transcription. Overexpression of miR-122 inhibited MDR1 expression via directly suppressing Wnt/β-catenin pathway.
CONCLUSION: Our study fully demonstrated that miR-122 inhibits MDR1 expression via suppression of Wnt/β-catenin pathway, thereby enhancing HCC sensitivity to OXA. Therefore, miR-122 could serve as a novel potential therapeutic target for HCC.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemosensitivity; HCC, miR-122; Oxaliplatin; Wnt/β-catenin signaling pathway

Mesh:

Substances:

Year:  2018        PMID: 30539797     DOI: 10.1016/j.yexmp.2018.10.009

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  14 in total

1.  miR-122 and miR-197 expressions in hepatic carcinoma patients before and after chemotherapy and their effect on patient prognosis.

Authors:  Gang Zhan; Hui Jiang; Rui Yang; Kai Yang
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

2.  MiR-325 Promotes Oxaliplatin-Induced Cytotoxicity Against Colorectal Cancer Through the HSPA12B/PI3K/AKT/Bcl-2 Pathway.

Authors:  Li Zhang; Heping Chen; Yueqiong Song; Qing Gu; Lu Zhang; Qin Xie; Jin Xu; Min Zhang
Journal:  Dig Dis Sci       Date:  2020-09-10       Impact factor: 3.199

Review 3.  How Dysregulated Ion Channels and Transporters Take a Hand in Esophageal, Liver, and Colorectal Cancer.

Authors:  Christian Stock
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

Review 4.  Non-Coding RNAs: Regulating Disease Progression and Therapy Resistance in Hepatocellular Carcinoma.

Authors:  Debashri Manna; Devanand Sarkar
Journal:  Cancers (Basel)       Date:  2020-05-15       Impact factor: 6.639

Review 5.  Teaching an old dog new tricks: reactivated developmental signaling pathways regulate ABCB1 and chemoresistance in cancer.

Authors:  Wing-Kee Lee; Thévenod Frank
Journal:  Cancer Drug Resist       Date:  2021-06-19

Review 6.  Intestinal Wnt in the transition from physiology to oncology.

Authors:  Julia Swoboda; Patrick Mittelsdorf; Yuan Chen; Ralf Weiskirchen; Johannes Stallhofer; Silke Schüle; Nikolaus Gassler
Journal:  World J Clin Oncol       Date:  2022-03-24

7.  MicroRNA-1246 by Targeting AXIN2 and GSK-3β Overcomes Drug Resistance and Induces Apoptosis in Chemo-resistant Leukemia Cells.

Authors:  Bei Xie; Linjing Li; Zhewen Zhang; Lei Zhao; Juan Cheng; Cunmin Zhou; Jie Cheng; Jing Yan; Jing Chen; Juan Yi; Bei Wang; Suya Jin; Hulai Wei
Journal:  J Cancer       Date:  2021-05-13       Impact factor: 4.207

8.  Inhibition of miR-19a partially reversed the resistance of colorectal cancer to oxaliplatin via PTEN/PI3K/AKT pathway.

Authors:  Ye Zhang; Xinxin Liu; Junying Zhang; Yuanyuan Xu; Jie Shao; Yue Hu; Peng Shu; Haibo Cheng
Journal:  Aging (Albany NY)       Date:  2020-03-25       Impact factor: 5.682

Review 9.  MicroRNA-Based Combinatorial Cancer Therapy: Effects of MicroRNAs on the Efficacy of Anti-Cancer Therapies.

Authors:  Hyun Ah Seo; Sokviseth Moeng; Seokmin Sim; Hyo Jeong Kuh; Soo Young Choi; Jong Kook Park
Journal:  Cells       Date:  2019-12-20       Impact factor: 6.600

Review 10.  mRNA Post-Transcriptional Regulation by AU-Rich Element-Binding Proteins in Liver Inflammation and Cancer.

Authors:  Dobrochna Dolicka; Cyril Sobolewski; Marta Correia de Sousa; Monika Gjorgjieva; Michelangelo Foti
Journal:  Int J Mol Sci       Date:  2020-09-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.